A Colorado federal judge has just made it a little tougher for biopharma companies to get pretrial injunctions based on trade secret allegations.

Judge Philip Brimmer on Wednesday turned away Array BioPharma’s attempt to immediately stop nine former employees from working with former collaboration partner Loxo Oncology Inc. Without evidence that the partnership has produced a drug ready for clinical trials, there were no grounds for an injunction. “Irreparable harm that may occur years in the future, and certainly not before a trial on the merits, does not warrant injunctive relief,” Brimmer wrote.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]